These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases. Li Z; Patil GS; Golubski ZE; Hori H; Tehrani K; Foreman JE; Eveleth DD; Bartus RT; Powers JC J Med Chem; 1993 Oct; 36(22):3472-80. PubMed ID: 8230139 [TBL] [Abstract][Full Text] [Related]
4. Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. Moldoveanu T; Campbell RL; Cuerrier D; Davies PL J Mol Biol; 2004 Nov; 343(5):1313-26. PubMed ID: 15491615 [TBL] [Abstract][Full Text] [Related]
5. Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Moldoveanu T; Gehring K; Green DR Nature; 2008 Nov; 456(7220):404-8. PubMed ID: 19020622 [TBL] [Abstract][Full Text] [Related]
6. Developments in the design and synthesis of calpain inhibitors. Neffe AT; Abell AD Curr Opin Drug Discov Devel; 2005 Nov; 8(6):684-700. PubMed ID: 16312145 [TBL] [Abstract][Full Text] [Related]
7. Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors. Ovat A; Li ZZ; Hampton CY; Asress SA; Fernández FM; Glass JD; Powers JC J Med Chem; 2010 Sep; 53(17):6326-36. PubMed ID: 20690647 [TBL] [Abstract][Full Text] [Related]
8. Development of calpain-specific inactivators by screening of positional scanning epoxide libraries. Cuerrier D; Moldoveanu T; Campbell RL; Kelly J; Yoruk B; Verhelst SHL; Greenbaum D; Bogyo M; Davies PL J Biol Chem; 2007 Mar; 282(13):9600-9611. PubMed ID: 17218315 [TBL] [Abstract][Full Text] [Related]
9. Structures of human calpain-3 protease core with and without bound inhibitor reveal mechanisms of calpain activation. Ye Q; Campbell RL; Davies PL J Biol Chem; 2018 Mar; 293(11):4056-4070. PubMed ID: 29382717 [TBL] [Abstract][Full Text] [Related]
10. Characterization of the intracellular proteolytic cleavage of myocilin and identification of calpain II as a myocilin-processing protease. Sánchez-Sánchez F; Martínez-Redondo F; Aroca-Aguilar JD; Coca-Prados M; Escribano J J Biol Chem; 2007 Sep; 282(38):27810-24. PubMed ID: 17650508 [TBL] [Abstract][Full Text] [Related]
11. Molecular modeling: a search for a calpain inhibitor as a new treatment for cataractogenesis. Stuart BG; Coxon JM; Morton JD; Abell AD; McDonald DQ; Aitken SG; Jones MA; Bickerstaffe R J Med Chem; 2011 Nov; 54(21):7503-22. PubMed ID: 21955158 [TBL] [Abstract][Full Text] [Related]
12. Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions. Cuerrier D; Moldoveanu T; Davies PL J Biol Chem; 2005 Dec; 280(49):40632-41. PubMed ID: 16216885 [TBL] [Abstract][Full Text] [Related]
13. Exploration of orally available calpain inhibitors. Part 3: Dipeptidyl alpha-ketoamide derivatives containing pyridine moiety. Shirasaki Y; Miyashita H; Yamaguchi M Bioorg Med Chem; 2006 Aug; 14(16):5691-8. PubMed ID: 16651001 [TBL] [Abstract][Full Text] [Related]
14. N-heterocyclic dipeptide aldehyde calpain inhibitors. Jones SA; Jones MA; McNabb SB; Aitken SG; Coxon JM; Abell AD Protein Pept Lett; 2009; 16(12):1466-72. PubMed ID: 20001909 [TBL] [Abstract][Full Text] [Related]
15. Crystallization and X-ray crystallographic analysis of m-calpain, a Ca2+-dependent protease. Hosfield CM; Ye Q; Arthur JS; Hegadorn C; Croall DE; Elce JS; Jia Z Acta Crystallogr D Biol Crystallogr; 1999 Aug; 55(Pt 8):1484-6. PubMed ID: 10417423 [TBL] [Abstract][Full Text] [Related]
16. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Hanna RA; Campbell RL; Davies PL Nature; 2008 Nov; 456(7220):409-12. PubMed ID: 19020623 [TBL] [Abstract][Full Text] [Related]
17. Exploration of cornea permeable calpain inhibitors as anticataract agents. Nakamura M; Yamaguchi M; Sakai O; Inoue J Bioorg Med Chem; 2003 Apr; 11(7):1371-9. PubMed ID: 12628663 [TBL] [Abstract][Full Text] [Related]
18. Structure-based design of allosteric calpain-1 inhibitors populating a novel bioactivity space. Kalash L; Cresser-Brown J; Habchi J; Morgan C; Miller DJ; Glen RC; Allemann RK; Bender A Eur J Med Chem; 2018 Sep; 157():1264-1275. PubMed ID: 30195237 [TBL] [Abstract][Full Text] [Related]
19. Predictions of Cleavability of Calpain Proteolysis by Quantitative Structure-Activity Relationship Analysis Using Newly Determined Cleavage Sites and Catalytic Efficiencies of an Oligopeptide Array. Shinkai-Ouchi F; Koyama S; Ono Y; Hata S; Ojima K; Shindo M; duVerle D; Ueno M; Kitamura F; Doi N; Takigawa I; Mamitsuka H; Sorimachi H Mol Cell Proteomics; 2016 Apr; 15(4):1262-80. PubMed ID: 26796116 [TBL] [Abstract][Full Text] [Related]
20. Exploration of the importance of the P2-P3-NHCO-moiety in a potent di- or tripeptide inhibitor of calpain I: insights into the development of nonpeptidic inhibitors of calpain I. Chatterjee S; Iqbal M; Mallya S; Senadhi SE; O'Kane TM; McKenna BA; Bozyczko-Coyne D; Kauer JC; Siman R; Mallamo JP Bioorg Med Chem; 1998 May; 6(5):509-22. PubMed ID: 9629465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]